Ignite Creation Date:
2025-12-24 @ 3:33 PM
Ignite Modification Date:
2026-03-01 @ 6:12 AM
Study NCT ID:
NCT00569192
Status:
COMPLETED
Last Update Posted:
2014-01-09
First Post:
2007-12-05
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study of 2 Doses of MAP0010 and Placebo in Asthmatic Children
Sponsor:
Allergan
Organization:
Study Overview
Official Title:
A Randomized, Double Blind, Placebo Controlled, Parallel Group, Study Investigating the Safety and Efficacy Over 12 Weeks Treatment Period of MAP0010 in Asthmatic Infants and Children 12 Months to 8 Years of Age
Status:
COMPLETED
Status Verified Date:
2013-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to examine the safety and efficacy of two doses of MAP0010 versus placebo in asthmatic infants and children, 12 months to 8 years of age, over a 12-week treatment period.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: